...
首页> 外文期刊>Biomolecules >Promising Directions in Atherosclerosis Treatment Based on Epigenetic Regulation Using MicroRNAs and Long Noncoding RNAs
【24h】

Promising Directions in Atherosclerosis Treatment Based on Epigenetic Regulation Using MicroRNAs and Long Noncoding RNAs

机译:基于MicroRNA和长度非编码RNA的表观遗传调节的动脉粥样硬化处理的有希望的方向

获取原文
           

摘要

Atherosclerosis is one of the leading causes of mortality from cardiovascular disease (CVD) and is a chronic inflammatory disease of the middle and large arteries caused by a disruption of lipid metabolism. Noncoding RNA (ncRNA), including microRNA (miRNA), small interfering RNA (siRNA) and long noncoding RNA (lncRNA), was investigated for the treatment of atherosclerosis. Regulation of the expression of noncoding RNA targets the constituent element of the pathogenesis of atherosclerosis. Currently, miRNA therapy commonly employs miRNA antagonists and mimic compounds. In this review, attention is focused on approaches to correcting molecular disorders based on the genetic regulation of the transcription of key genes responsible for the development of atherosclerosis. Promising technologies were considered for the treatment of atherosclerosis, and examples are given for technologies that have been shown to be effective in clinical trials.
机译:动脉粥样硬化是心血管疾病(CVD)死亡率的主要原因之一,是由于脂质代谢的破坏引起的中大动脉的慢性炎症疾病。研究了NOD调节RNA(NCRNA),包括MICRRNA(miRNA),小干扰RNA(siRNA)和长的非分量RNA(LNCRNA),用于治疗动脉粥样硬化。非分子RNA表达的调节靶向动脉粥样硬化的发病机制的组成元素。目前,miRNA治疗通常使用miRNA拮抗剂和模拟化合物。在本综述中,关注基于校正分子紊乱的方法,根据负责动脉粥样硬化发育的关键基因转录的遗传调节。考虑治疗动脉粥样硬化的有前途的技术,并给出了在临床试验中有效有效的技术的实例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号